268 related articles for article (PubMed ID: 33367900)
1. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
[TBL] [Abstract][Full Text] [Related]
2. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
[TBL] [Abstract][Full Text] [Related]
4. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
[TBL] [Abstract][Full Text] [Related]
5. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
Glintborg B; Di Giuseppe D; Wallman JK; Provan SA; Nordström D; Hokkanen AM; Österlund J; Kristianslund E; Kvien TK; Gudbjornsson B; Hetland ML; Michelsen B; Jacobsson L; Askling J; Lindström U
Rheumatology (Oxford); 2023 Feb; 62(2):647-658. PubMed ID: 35723604
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
[TBL] [Abstract][Full Text] [Related]
7. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
[TBL] [Abstract][Full Text] [Related]
8. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
11. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
13. Effects of TNF-α inhibition
Elliott A; Wright G; Pendleton A; Rooney M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab: A Review in Psoriatic Arthritis.
Blair HA
Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
[TBL] [Abstract][Full Text] [Related]
15. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
[TBL] [Abstract][Full Text] [Related]
19. A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis.
Jiménez-Morales A; Cáliz R; Aceituno S; Prades M; Blanch C
Reumatol Clin (Engl Ed); 2021 Nov; 17(9):536-542. PubMed ID: 34756316
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]